Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000
Debt
Debt-to-Equity Ratio0.14
Current Ratio14.50
Quick Ratio14.50
Price-To-Earnings
Trailing P/E Ratio-10.02
Forward P/E Ratio-9.95
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.73 million
Price / Sales103.69
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book6.51
Profitability
EPS (Most Recent Fiscal Year)($2.98)
Net Income$-120,320,000.00
Net Margins-623.35%
Return on Equity-61.27%
Return on Assets-35.09%
Miscellaneous
Employees112
Outstanding Shares47,680,000
Market Cap$1.41 billion
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine Inc (NASDAQ:EDIT) issued its earnings results on Monday, August, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.15. The company had revenue of $7.37 million for the quarter, compared to the consensus estimate of $7.01 million. Editas Medicine had a negative return on equity of 61.27% and a negative net margin of 623.35%. The firm's revenue was up 137.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.65) earnings per share. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
9 brokers have issued 1 year price targets for Editas Medicine's stock. Their forecasts range from $36.00 to $67.00. On average, they expect Editas Medicine's stock price to reach $48.6667 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price. View Analyst Price Targets for Editas Medicine.
What is the consensus analysts' recommendation for Editas Medicine?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Editas Medicine.
What are Wall Street analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (8/9/2018)
- 2. Cann analysts commented, "Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board." (2/16/2018)
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI).
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Ms. Katrine S. Bosley, CEO, Pres & Director (Age 50)
- Dr. Andrew A. F. Hack, Chief Financial Officer (Age 44)
- Dr. Charles Albright, Chief Scientific Officer (Age 60)
- Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
- Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 64)
When did Editas Medicine IPO?
(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Has Editas Medicine been receiving favorable news coverage?
Media coverage about EDIT stock has been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Editas Medicine earned a media and rumor sentiment score of 0.20 on Accern's scale. They also gave media headlines about the company an impact score of 48.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Editas Medicine.
Who are Editas Medicine's major shareholders?
Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.31%), FMR LLC (6.12%), ARK Investment Management LLC (4.62%), Morgan Stanley (4.34%), Global Thematic Partners LLC (1.07%) and Chevy Chase Trust Holdings Inc. (0.95%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman, Kevin P Starr, Polaris Venture Management Co and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.
Which institutional investors are selling Editas Medicine stock?
EDIT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Bank of New York Mellon Corp, SG Americas Securities LLC, Carnegie Capital Asset Management LLC, Capital Advisors Inc. OK, Fiera Capital Corp and Victory Capital Management Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.
Which institutional investors are buying Editas Medicine stock?
EDIT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., ARK Investment Management LLC, Morgan Stanley, JS Capital Management LLC, Handelsbanken Fonder AB, First Trust Advisors LP, Fiduciary Trust Co. and Korea Investment CORP. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $29.86.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.41 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
